価格表

在庫・価格 : 2025年06月08日 05時19分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Osteoprotegerin/Fc Chimera, Mouse, Recombinant, Carrier-free
データシート
459-MO-100 RSDアールアンドディー システムズ
R&D Systems, Inc.
100 μg ¥90,000
(未発注)
追加

在庫・価格 : 2025年06月08日 05時19分 現在

Osteoprotegerin/Fc Chimera, Mouse, Recombinant, Carrier-free

  • 商品コード:459-MO-100
  • メーカー:RSD
  • 包装:100μg
  • 価格: ¥90,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Toraldo G et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc. Natl. Acad. Sci. U.S.A. 2003 Jan;100(1):125-30
Toraldo G et al
2003/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
2 Cao J et al. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J. Bone Miner. Res. 2003 Feb;18(2):270-7
Cao J et al
2003/01/01
Application: Western Blot PubMed
3 Karst M et al. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J. Cell. Physiol. 2004 Jul;200(1):99-106
Karst M et al
2004/01/01
Species: Mouse, Application: Bioassay, Sample type: Whole Cells PubMed
4 Bengtsson AK et al. 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood 2004 Sep;104(5):1404-10
Bengtsson AK et al
2004/01/01
Application: ELISA Standard PubMed
5 Ishizuka K et al. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. Neurosci. Lett. 2005 Apr;379(1):47-51
Ishizuka K et al
2005/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
6 Gustafsson BI et al. Serotonin and fluoxetine modulate bone cell function in vitro. J. Cell. Biochem. 2006 May;98(1):139-51
Gustafsson BI et al
2006/01/01
Application: ELISA Standard PubMed
7 Berry JE et al. JunB as a downstream mediator of PTHrP actions in cementoblasts. J. Bone Miner. Res. 2006 Feb;21(2):246-57
Berry JE et al
2006/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
8 Nakamichi Y et al. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J. Immunol. 2007 Jan;178(1):192-200
Nakamichi Y et al
2007/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
9 Schrader J et al. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia 2007 Jun;50(6):1243-7
Schrader J et al
2007/01/01
Species: Rat, Application: Bioassay, Sample type: Whole Cells PubMed
10 Onal M et al. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J. Biol. Chem. 2012 Aug;287(35):29851-60
Onal M et al
2012/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
11 Charles JF et al. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J. Clin. Invest. 2012 Dec;122(12):4592-605
Charles JF et al
2012/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
12 Rementer CW et al. An inducible, ligand-independent receptor activator of NF-κB gene to control osteoclast differentiation from monocytic precursors. PLoS ONE 2013;8(12):e84465
Rementer CW et al
2013/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
13 Takeshita S et al. Age-related marrow adipogenesis is linked to increased expression of RANKL. J. Biol. Chem. 2014 Jun;289(24):16699-710
Takeshita S et al
2014/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
14 Mukai T et al. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss. J. Bone Miner. Res. 2014 Dec;29(12):2618-35
Mukai T et al
2014/01/01
Application: Neutralization, Sample Type: recombinant protein PubMed
15 Matsushita M et al. A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts. PLoS ONE 2015;10(1):e0116135
Matsushita M et al
2015/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
16 Ealba EL et al. Neural crest-mediated bone resorption is a determinant of species-specific jaw length. Dev. Biol. 2015 Dec;408(1):151-63
Ealba EL et al
2015/01/01
Application: In Vivo, Sample Type: In Vivo PubMed
  • No.: 1
  • 文献情報:
    Toraldo G et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc. Natl. Acad. Sci. U.S.A. 2003 Jan;100(1):125-30
    Toraldo G et al
    2003/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Cao J et al. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J. Bone Miner. Res. 2003 Feb;18(2):270-7
    Cao J et al
    2003/01/01
  • 備考:
    Application: Western Blot
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Karst M et al. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J. Cell. Physiol. 2004 Jul;200(1):99-106
    Karst M et al
    2004/01/01
  • 備考:
    Species: Mouse, Application: Bioassay, Sample type: Whole Cells
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Bengtsson AK et al. 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood 2004 Sep;104(5):1404-10
    Bengtsson AK et al
    2004/01/01
  • 備考:
    Application: ELISA Standard
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Ishizuka K et al. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. Neurosci. Lett. 2005 Apr;379(1):47-51
    Ishizuka K et al
    2005/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Gustafsson BI et al. Serotonin and fluoxetine modulate bone cell function in vitro. J. Cell. Biochem. 2006 May;98(1):139-51
    Gustafsson BI et al
    2006/01/01
  • 備考:
    Application: ELISA Standard
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Berry JE et al. JunB as a downstream mediator of PTHrP actions in cementoblasts. J. Bone Miner. Res. 2006 Feb;21(2):246-57
    Berry JE et al
    2006/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Nakamichi Y et al. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J. Immunol. 2007 Jan;178(1):192-200
    Nakamichi Y et al
    2007/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Schrader J et al. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia 2007 Jun;50(6):1243-7
    Schrader J et al
    2007/01/01
  • 備考:
    Species: Rat, Application: Bioassay, Sample type: Whole Cells
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Onal M et al. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J. Biol. Chem. 2012 Aug;287(35):29851-60
    Onal M et al
    2012/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Charles JF et al. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J. Clin. Invest. 2012 Dec;122(12):4592-605
    Charles JF et al
    2012/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Rementer CW et al. An inducible, ligand-independent receptor activator of NF-κB gene to control osteoclast differentiation from monocytic precursors. PLoS ONE 2013;8(12):e84465
    Rementer CW et al
    2013/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Takeshita S et al. Age-related marrow adipogenesis is linked to increased expression of RANKL. J. Biol. Chem. 2014 Jun;289(24):16699-710
    Takeshita S et al
    2014/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Mukai T et al. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss. J. Bone Miner. Res. 2014 Dec;29(12):2618-35
    Mukai T et al
    2014/01/01
  • 備考:
    Application: Neutralization, Sample Type: recombinant protein
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Matsushita M et al. A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts. PLoS ONE 2015;10(1):e0116135
    Matsushita M et al
    2015/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Ealba EL et al. Neural crest-mediated bone resorption is a determinant of species-specific jaw length. Dev. Biol. 2015 Dec;408(1):151-63
    Ealba EL et al
    2015/01/01
  • 備考:
    Application: In Vivo, Sample Type: In Vivo
  • 参照:
    PubMed